Related Experiment Video

Updated: May 11, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.1K

Serendipity in Neuro-Oncology: The Evolution of Chemotherapeutic Agents

Denise Nadora1, Shawyon Ezzati1, Brandon Bol1

  • 1College of Medicine, California Northstate University, Elk Grove, CA 95757, USA.

International Journal of Molecular Sciences
|April 17, 2025
PubMed

Insights

Neuro-oncology drug discovery faces challenges, with targeted therapies showing limited success. Embracing serendipity alongside rational design may improve outcomes for brain tumor treatments.

Area of Science:

  • Neuro-oncology
  • Drug Discovery
  • Translational Medicine

Background:

  • Novel therapeutics for brain tumors, especially gliomas, are challenging to develop.
  • Targeted therapies have yielded limited clinical success due to tumor complexity.
  • High costs and low success rates characterize neuro-oncology drug development.

Purpose of the Study:

  • To critically examine the landscape of neuro-oncology drug discovery.
  • To highlight the role of serendipity in identifying impactful therapies.
  • To propose integrating chance discoveries with rational design for enhanced success.

Main Methods:

  • Review of historical and contemporary neuro-oncology drug discovery cases.
  • Analysis of instances where repurposed drugs or off-target effects yielded benefits.
  • Examination of the impact of serendipitous findings on therapeutic development.

Main Results:

  • Rational drug design targeting specific pathways has shown sparse clinical success.
  • Serendipitous discoveries, including repurposed drugs and beneficial off-target effects, have led to breakthroughs.
  • Chance has played a significant role in the development of impactful neuro-oncology therapies.

Conclusions:

  • The complex nature of brain tumors necessitates exploring diverse discovery avenues.
  • Integrating serendipity with rational drug design may accelerate progress in neuro-oncology.
  • Future neuro-oncology therapeutic development could benefit from embracing unexpected findings.
Keywords:
Chemotherapy in CNS tumorsdrug repurposing in oncologyserendipitous drug discovery

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
137